title: Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer.
abstract: The sonication-assisted layer-by-layer (SLBL) technology was developed to combine necessary factors for an efficient drug-delivery system: (i) control of nanocolloid size within 100 - 300 nm, (ii) high drug content (70% wt), (iii) shell biocompatibility and biodegradability, (iv) sustained controlled release, and (v) multidrug-loaded system. Stable nanocolloids of Paclitaxel (PTX) and lapatinib were prepared by the SLBL method. In a multidrug-resistant (MDR) ovarian cancer cell line, OVCAR-3, lapatinib/PTX nanocolloids mediated an enhanced cell growth inhibition in comparison with the PTX-only treatment. A series of in vitro cell assays were used to test the efficacy of these formulations. The small size and functional versatility of these nanoparticles, combined with their ability to incorporate various drugs, indicates that lapatinib/PTX nanocolloids may have in vivo therapeutic applications.
authors.affiliation: Laboratory of General Physiology, Department of Biological and Environmental Sciences and Technologies, University of Salento, Lecce, Italy.
authors.forename: Daniele
authors.initials: D
authors.lastname: Vergara
authors.forename: Claudia
authors.initials: C
authors.lastname: Bellomo
authors.forename: Xingcai
authors.initials: X
authors.lastname: Zhang
authors.forename: Viviana
authors.initials: V
authors.lastname: Vergaro
authors.forename: Andrea
authors.initials: A
authors.lastname: Tinelli
authors.forename: Vito
authors.initials: V
authors.lastname: Lorusso
authors.forename: Ross
authors.initials: R
authors.lastname: Rinaldi
authors.forename: Yuri M
authors.initials: YM
authors.lastname: Lvov
authors.forename: Stefano
authors.initials: S
authors.lastname: Leporatti
authors.forename: Michele
authors.initials: M
authors.lastname: Maffia
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D003102:Colloids / Q000737:chemistry*; D018432:Drug Resistance, Multiple / Q000187:drug effects; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D005260:Female; D006801:Humans; D000077341:Lapatinib; D053769:Nanocapsules / Q000737:chemistry*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D017239:Paclitaxel; D011799:Quinazolines / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D003102:Colloids; D053769:Nanocapsules; D011799:Quinazolines; D000077341:Lapatinib; D017239:Paclitaxel